MedTrace Logo

Increasing HAART-Induced Immune Restoration With Cyclosporine

NCT00031070 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2015-03-09

No results posted yet for this study

Summary

The purpose of this study is to see if cyclosporine, taken when a patient begins highly active antiretroviral therapy (HAART), increases the number of CD4 T-cells (blood cells that fight infection) in a patient's blood. This study also will explore the safety of briefly giving cyclosporine to patients starting HAART.

Conditions

  • HIV Infections

Interventions

DRUG

Abacavir sulfate, Lamivudine and Zidovudine

DRUG

Cyclosporine

BIOLOGICAL

Hepatitis A Vaccine (Inactivated)

DRUG

Efavirenz

BIOLOGICAL

Pneumococcal Conjugate Vaccine, Heptavalent

BIOLOGICAL

Rabies Vaccine

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Michael Lederman, M.D. · Case Western Reserve University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Completion
2006-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00031070 on ClinicalTrials.gov